1. (1) As used in this section, "exome sequence testing" means a genomic technique for sequencing the genome of an individual for diagnostic purposes.

2. (2) The Medicaid program shall reimburse for exome sequence testing:

   1. (a) for an enrollee who:

      1. (i) is younger than 21 years old; and
      2. (ii) who remains undiagnosed after exhausting all other appropriate diagnostic-related tests;
   2. (b) performed by a nationally recognized provider with significant experience in exome sequence testing;
   3. (c) that is medically necessary; and
   4. (d) at a rate set by the Medicaid program.

Renumbered and Amended by Chapter 306, 2023 General Session